Botulinum A Toxin Intravesical Injection in Patients With Painful Bladder Syndrome: 1-Year Followup

Giannantoni, Antonella; Porena, Massimo; Costantini, Elisabetta; Zucchi, Alessandro; Mearini, Luigi; Mearini, Ettore

doi:10.1016/j.juro.2007.10.032

Cited by 127 publications

(83 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As far as the long-lasting results of resiniferatoxin are concerned, the beneficial effects reported by the reviewed studies were still present, though decreased, at the 12-week follow-up end points. The same is true about another treatment option: intravesical administration of botulinum toxin type A. Giannantoni et al [30], in a recent study, concluded that this regimen was effective for short-term management of refractory interstitial cystitis and that the beneficial effects decreased progressively within a few months after treatment.…”

Section: Discussionmentioning

confidence: 98%

Resiniferatoxin in the treatment of interstitial cystitis: a systematic review

2008

View full text Add to dashboard Cite

Resiniferatoxin, a treatment based on a physiopathological concept (the involvement of C fibers and transient receptor potential vanilloid 1 in the transmission of pain) is undergoing evaluation for interstitial cystitis. We evaluated the current evidence from relevant studies identified in PubMed and Scopus databases. Six studies provided contradictory results regarding the effectiveness of resiniferatoxin treatment. The largest study showed no improvement of overall symptoms following a single administration of resiniferatoxin. Three other articles that studied the effectiveness of a single dose of resiniferatoxin gave contradictory results. However, the other two studies, those that examined the effect of multiple or prolonged administration schemes, gave more encouraging results. The use of the regimen is generally well tolerated although mild adverse events such as increase of bladder pain during instillation were sometimes reported by patients and serious adverse events rarely occur. In conclusion, the effectiveness of resiniferatoxin in the treatment of interstitial cystitis remains unknown.

show abstract

Section: Discussionmentioning

confidence: 98%

Resiniferatoxin in the treatment of interstitial cystitis: a systematic review

2008

View full text Add to dashboard Cite

show abstract

“…In a prospective study of effect of botulinum toxin A in painful bladder syndrome, at 1 year follow up, it was seen that the beneficial effect lasted at 3 months in 86% and 30% at 5 months. There was a significant decrease in pain, accompanied by increase in maximum cystometric capacity and in day time and night time urinary frequency, but after 1 year pain had recurred in all, requiring repeat injection [51]. However, this requires confirmation by a randomized placebo controlled study.…”

Section: Urinary Bladder Dysfunctionmentioning

confidence: 93%

Therapeutic Application of Botulinum Toxin in Clinical Practice

Dash¹,

Araf²

2009

TOGMJ

View full text Add to dashboard Cite

Botulinum toxin, one of the most potent toxins known, is produced by Clostridium botulinum. It causes a temporary paralysis of muscles by inhibiting vesicular release of acetylcholine in neuromuscular junction and synaptic transmission at cholinergic nerve terminals and causes a temporary paralysis of muscles. Since the approval of botulinum toxin A by FDA for strabismus and blepharospasm in 1989 and botulinum toxin B for cervical dystonia in 2000, its therapeutic uses are expanding. To date, both the serotypes A and B have been used therapeutically. These include various dystonic movement disorders, lacrimal hypersecretion, hyperhydrosis, overactive bladder syndromes both neurogenic and idiopathic, prostatic hyperplasia, various gastrointestinal disorders, headache syndromes like migraine and various spastic disorders. Botulinum toxin does not correct the underlying pathology but only produces clinically symptomatic improvement. The duration of improvement and the percentage of improvement vary between different studies due to differences in doses used; different techniques used for injections and also the dilutions. Still more trials are required to explore newer indications of its use, to find out the exact effective doses, dilutions and techniques, so as to have a prolonged clinical improvement. Though it has a good safety profile, complications are related to chemodenervation of adjacent muscles and injection techniques. This article provides an update on different uses of botulinum toxin in medicine.

show abstract

“…Giannantoni et al (36) reported that 200 IU BoNT-A injected into the detrusor muscle in patients with BPS provided significant improvement in pain, urinary frequency, voided volume, and bladder capacity; however, all patients had recurrent basal complaints at the end of the first year. In a randomized controlled trial including 67 patients (56 females, 11 males) by Kuo and Chancellor (37), BoNT-A injections (100 IU and 200 IU) with or without hydrodistension were compared.…”

Section: -Interstitial Cystitis/bladder Pain Syndromementioning

confidence: 99%

Use of botulinum toxin in urology: a literature review

Bayrak¹,

Şeçkiner²,

Onur³

et al. 2018

Eur J Ther

View full text Add to dashboard Cite

Botulinum neurotoxin (BoNT) is currently preferred as a minimally invasive treatment for lower urinary tract pathologies. Although BoNT injections have become widespread globally for the past 5 years, today, the urological use of BoNT Type A (BoNT-A) is only licensed for the treatment of neurogenic detrusor overactivity and overactive bladder. Despite the relative evidence for the use of BoNT-A in benign prostatic enlargement, there is no high-level evidence data for the use in detrusor sphincter dyssynergia, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. In this comprehensive review, we mention the mechanism of action and efficacy of BoNT in various urological disorders, present the reliability, and evaluate the literature data supporting its use.

show abstract

Botulinum A Toxin Intravesical Injection in Patients With Painful Bladder Syndrome: 1-Year Followup

Cited by 127 publications

References 18 publications

Resiniferatoxin in the treatment of interstitial cystitis: a systematic review

Resiniferatoxin in the treatment of interstitial cystitis: a systematic review

Therapeutic Application of Botulinum Toxin in Clinical Practice

Use of botulinum toxin in urology: a literature review

Contact Info

Product

Resources

About